Literature DB >> 21703766

Reducing the future threat from (liver) fluke: realistic prospect or quixotic fantasy?

Ian Fairweather1.   

Abstract

The liver fluke remains an economically significant parasite of livestock and is emerging as an important zoonotic infection of humans. The incidence of the disease has increased in the last few years, as a possible consequence of changes to the World's climate. Future predictions suggest that this trend is likely to continue. Allied to the changing pattern of disease, reports of resistance to triclabendazole (TCBZ) have appeared in the literature, although they do not all represent genuine cases of resistance. Nevertheless, any reports of resistance are a concern, because triclabendazole is the only drug that has high activity against the migratory and damaging juvenile stages of infection. How to deal with the twin problems (of increasing incidence and drug resistance) is the overall theme of the session on "Trematodes: Fasciola hepatica epidemiology and control" and of this review to introduce the session. Greater knowledge of fluke epidemiology and population genetics will highlight those regions where surveillance is most required and indicate how quickly resistant populations of fluke may arise. Models of disease risk are becoming increasingly sophisticated and precise, with more refined data analysis programmes and Geographic Information Systems (GIS) data. Recent improvements have been made in our understanding of the action of triclabendazole and the ways in which flukes have become resistant to it. While microtubules are the most likely target for drug action, tubulin mutations do not seem to be involved in the resistance mechanism. Rather, upregulation of drug uptake and metabolism processes appear to be more important and the data relating to them will be discussed. The information may help in the design of new treatment strategies or pinpoint potential molecular markers for monitoring fluke populations. Advances in the identification of novel targets for drugs and vaccines will be made by the various "-omics" technologies that are now being applied to Fasciola. A major area of concern in the current control of fasciolosis is the lack of reliable tests for the diagnosis of drug (TCBZ) resistance. This has led to inaccurate reports of resistance, which is hindering successful disease management, as farmers may be encouraged to switch to less effective drugs. Progress with the development of a number of new diagnostic tests will be reviewed.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21703766     DOI: 10.1016/j.vetpar.2011.05.034

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  26 in total

1.  A mucin-like peptide from Fasciola hepatica induces parasite-specific Th1-type cell immunity.

Authors:  Verónica Noya; Natalie Brossard; Patricia Berasaín; Ernesto Rodríguez; Carolina Chiale; Daniel Mazal; Carlos Carmona; Teresa Freire
Journal:  Parasitol Res       Date:  2015-12-05       Impact factor: 2.289

2.  Seasonal variation of Fasciola hepatica antibodies in dairy herds in Northern Ireland measured by bulk tank milk ELISA.

Authors:  Andrew W Byrne; Jordon Graham; James McConville; Georgina Milne; Stanley McDowell; Robert E B Hanna; Maria Guelbenzu-Gonzalo
Journal:  Parasitol Res       Date:  2018-06-14       Impact factor: 2.289

3.  Field study on the determination of the effective dose of injectable fosfatriclaben prodrug in sheep naturally infected with Fasciola hepatica.

Authors:  Froylán Ibarra-Velarde; Tania Rojas-Campos; Yolanda Vera-Montenegro; Miguel Flores-Ramos; Rafael Castillo; Gerardo Leyva-Gómez
Journal:  Parasitol Res       Date:  2021-11-05       Impact factor: 2.289

Review 4.  Fasciolosis-An Increasing Challenge in the Sheep Industry.

Authors:  Snorre Stuen; Cecilie Ersdal
Journal:  Animals (Basel)       Date:  2022-06-08       Impact factor: 3.231

5.  Pharmacokinetics of the fasciocidal drug candidates MT04 and OZ78 in uninfected rats and in vitro pharmacodynamic studies.

Authors:  Carla Kirchhofer; Mireille Vargas; Jörg Huwyler; Jennifer Keiser
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-04-14       Impact factor: 4.077

6.  Evidence of population structuring following population genetic analyses of Fasciola hepatica from Argentina.

Authors:  Nicola J Beesley; Elizabeth Attree; Severo Vázquez-Prieto; Román Vilas; Esperanza Paniagua; Florencio M Ubeira; Oscar Jensen; Cesar Pruzzo; José D Álvarez; Jorge Bruno Malandrini; Hugo Solana; Jane E Hodgkinson
Journal:  Int J Parasitol       Date:  2021-02-11       Impact factor: 3.981

Review 7.  A research agenda for helminth diseases of humans: intervention for control and elimination.

Authors:  Roger K Prichard; María-Gloria Basáñez; Boakye A Boatin; James S McCarthy; Héctor H García; Guo-Jing Yang; Banchob Sripa; Sara Lustigman
Journal:  PLoS Negl Trop Dis       Date:  2012-04-24

8.  Apparent triclabendazole-resistant human Fasciola hepatica infection, the Netherlands.

Authors:  Annemarie J S Winkelhagen; Theo Mank; Peter J de Vries; Robin Soetekouw
Journal:  Emerg Infect Dis       Date:  2012-06       Impact factor: 6.883

9.  Fasciola hepatica vaccine: we may not be there yet but we're on the right road.

Authors:  Verónica Molina-Hernández; Grace Mulcahy; Jose Pérez; Álvaro Martínez-Moreno; Sheila Donnelly; Sandra M O'Neill; John P Dalton; Krystyna Cwiklinski
Journal:  Vet Parasitol       Date:  2015-01-15       Impact factor: 2.738

10.  Integrating fasciolosis control in the dry cow management: the effect of closantel treatment on milk production.

Authors:  Johannes Charlier; Miel Hostens; Jos Jacobs; Bonny Van Ranst; Luc Duchateau; Jozef Vercruysse
Journal:  PLoS One       Date:  2012-08-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.